BrainStorm Cell Therapeutics Inc. (BCLI) stock
BCLIOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.77−0.01 (-1.17%)
Close on Oct 19, 2026Market cap $8.50MP/E –Yield –
BrainStorm Cell Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
BrainStorm Cell Therapeutics's price to book ratio was 47.9× on Jan 31, 2023, against 4.5× a year earlier. Over the last 5 years it ranged from 3.4× to 264.4×, with a median of 10.2×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Jan 31, 2023 | 47.9× | +4.7 |
| 2022 | Dec 30, 2022 | 43.2× | +37.4 |
| 2021 | Dec 31, 2021 | 5.8× | +0.3 |
| 2020 | Dec 31, 2020 | 5.5× | −258.8 |
| 2019 | Jul 31, 2019 | 264.4× | +257.0 |
| 2018 | Dec 31, 2018 | 7.4× | −6.9 |
| 2017 | Dec 29, 2017 | 14.2× | +9.7 |
| 2016 | Dec 30, 2016 | 4.5× | +1.1 |
| 2015 | Dec 31, 2015 | 3.4× | −4.7 |
| 2014 | Dec 31, 2014 | 8.1× | +1.1 |
| 2013 | Dec 31, 2013 | 7.0× | −0.4 |
| 2012 | Dec 31, 2012 | 7.4× | −3.9 |
| 2011 | Dec 30, 2011 | 11.3× | – |
See a number that looks wrong?